Pharmaceutical News and Articles

AAAAI: Omalizumab Superior to Oral Immunotherapy in Multifood Allergy

Omalizumab is superior to oral immunotherapy (OIT) for multifood allergy, and most patients include dietary consumption (DC) of allergy-triggering foods after g

Depemokimab Applications Accepted for Review by the US FDA for Asthma with Type 2 Inflammation and for Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

Injectable Drug Resolves Dangerous Food Allergies In One-Third Of Kids

More than a third of food-allergic kids were able to eat full servings of their trigger foods after treatment with an injectable asthma drug, new clinical trial

Instagram, TikTok Feature "Overwhelmingly" Misleading Medical Info

Heard the latest on social media about testosterone testing, full-body MRI scans, egg timer female fertility tests or gut microbiome analysis If so, you ve more

Death Risk Doubled For ER Patients On Psychedelics

People who land in the ER after using hallucinogens are more than twice as likely to die in a handful of years, a new study says. Psychedelics users treated at

Patients Devastated When Docs Dismiss Autoimmune Ailments As Psychosomatic

A patient with multiple autoimmune diseases can remember the exact moment a doctor tore their heart out. One doctor told me I was making myself feel pain, and I

Exercise Boosts Mental Health Of Women With Chronic Pelvic Pain

Physical activity can improve the mental well-being of women living with chronic pelvic pain disorders like endometriosis and uterine fibroids, a new study says

Depemokimab Delivers Clinically Meaningful and Statistically Significant Improvements for Patients with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

GSK plc (LSE NYSE GSK) today announced full results from the positive ANCHOR-1 and ANCHOR-2 phase III clinical trials assessing the efficacy and safety of depem

Indivior Announces FDA Approval of Label Changes for Sublocade (buprenorphine extended-release) Injection

Monthly News Roundup - February 2025

FDA Updates Izervay Label to Lengthen Treatment Duration for Geographic Atrophy Izervay (avacincaptad pegol) from Astellas is now FDA-approved without a limitat